DE69330137D1 - Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs - Google Patents
Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebsInfo
- Publication number
- DE69330137D1 DE69330137D1 DE69330137T DE69330137T DE69330137D1 DE 69330137 D1 DE69330137 D1 DE 69330137D1 DE 69330137 T DE69330137 T DE 69330137T DE 69330137 T DE69330137 T DE 69330137T DE 69330137 D1 DE69330137 D1 DE 69330137D1
- Authority
- DE
- Germany
- Prior art keywords
- combination
- oligonucleotide
- treating cancer
- antisense oligonucleotides
- antineoplastic agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96567192A | 1992-10-21 | 1992-10-21 | |
PCT/US1993/007541 WO1994008625A1 (en) | 1992-10-21 | 1993-08-10 | Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69330137D1 true DE69330137D1 (de) | 2001-05-17 |
DE69330137T2 DE69330137T2 (de) | 2001-11-15 |
Family
ID=25510318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69330137T Ceased DE69330137T2 (de) | 1992-10-21 | 1993-08-10 | Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0668782B1 (de) |
JP (1) | JPH08506087A (de) |
AT (1) | ATE200427T1 (de) |
AU (1) | AU5005093A (de) |
CA (1) | CA2147663A1 (de) |
DE (1) | DE69330137T2 (de) |
WO (1) | WO1994008625A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE258596T1 (de) | 1993-07-10 | 2004-02-15 | Biognostik Ges | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen |
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
EP0932698A1 (de) * | 1996-03-26 | 1999-08-04 | Lynx Therapeutics, Inc. | Oligonukleotide zusammenstellungen zur behandlung von menschlichem melanom |
EP0941124A4 (de) * | 1996-11-21 | 2004-12-15 | Univ Nebraska | Antisense-oligonukleotid zusammenstellungen zur gezielten tötung von krebszellen |
HUP0100044A3 (en) * | 1997-05-05 | 2003-08-28 | Sanofi Aventis Deutschland | Modified antisense nucleotides complementary to a section of the human ha-ras gene |
US7087580B2 (en) | 1998-04-23 | 2006-08-08 | Genesense Technologies, Inc. | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
US6417169B1 (en) * | 1998-04-23 | 2002-07-09 | Genesense Technologies Inc. | Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth |
US6953783B1 (en) | 1998-10-19 | 2005-10-11 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
AU2004200032B2 (en) * | 1998-10-19 | 2005-05-05 | Methylgene, Inc | Modulation of gene expression by combination therapy |
EP1243290A3 (de) * | 1998-10-19 | 2004-03-17 | Methylgene, Inc. | Veränderung der Genexpression durch Kombinationstherapie |
CA2347003A1 (en) * | 1998-10-19 | 2000-04-27 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5055459A (en) * | 1986-06-30 | 1991-10-08 | Board Of Regents, The University Of Texas | Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
-
1993
- 1993-08-10 EP EP93919965A patent/EP0668782B1/de not_active Expired - Lifetime
- 1993-08-10 AU AU50050/93A patent/AU5005093A/en not_active Abandoned
- 1993-08-10 WO PCT/US1993/007541 patent/WO1994008625A1/en active IP Right Grant
- 1993-08-10 CA CA002147663A patent/CA2147663A1/en not_active Withdrawn
- 1993-08-10 JP JP6509970A patent/JPH08506087A/ja active Pending
- 1993-08-10 DE DE69330137T patent/DE69330137T2/de not_active Ceased
- 1993-08-10 AT AT93919965T patent/ATE200427T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPH08506087A (ja) | 1996-07-02 |
DE69330137T2 (de) | 2001-11-15 |
AU5005093A (en) | 1994-05-09 |
EP0668782A4 (de) | 1998-09-16 |
EP0668782B1 (de) | 2001-04-11 |
WO1994008625A1 (en) | 1994-04-28 |
CA2147663A1 (en) | 1994-04-28 |
EP0668782A1 (de) | 1995-08-30 |
ATE200427T1 (de) | 2001-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69330137D1 (de) | Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs | |
ATE194383T1 (de) | Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs | |
ZA200304500B (en) | Method for inhibiting the expression of a target gene and medicament for treating a tumor disease. | |
DK1163254T3 (da) | TRPM-2 antisense-behandling | |
HU9403788D0 (en) | Self-stabilized oligonucleotides as therapeutic agents | |
EP0939621A4 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
TR199801581T2 (xx) | �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler. | |
HU9501963D0 (en) | 7-deazapurine modified oligonucleotides | |
DE69819167D1 (de) | Modifizierter, das dorsalgewebe beeinflussender faktor | |
MXPA03008623A (es) | Combinacion farmaceutica para el tratamiento del cancer. | |
PT1053313E (pt) | Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase | |
DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
DE69328025D1 (de) | Dorsalgewebe beeinflussender faktor und zusammensetzungen | |
BR0008788A (pt) | Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase | |
FR2790757B1 (fr) | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. | |
WO1999007844A3 (en) | Methods and compositions for treatment of restenosis | |
PT775745E (pt) | Aptameros inibidores de catepsina g | |
DE69841858D1 (de) | Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten | |
ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
WO2003030832A3 (en) | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer | |
WO1999025819A3 (de) | Antisense oligonukleotide gegen tenascin zur behandlung von vitiligo | |
AU2180501A (en) | Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide | |
DE10346721A1 (de) | Oligonukleotide, diese enthaltende Mittel und deren Verwendung | |
ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8310 | Action for declaration of annulment | ||
8311 | Complete invalidation |